Recursion Pharmaceuticals

Biotech · Salt Lake City, UT · Public

$1.1B raised

Trust

IPO Ready

Momentum

IPO Readiness Assessment

12%

✗

CFO Hired+15pts

No CFO identified

✗

General Counsel+10pts

No GC identified

✗

VP Sales / CRO+10pts

No sales leadership identified

✗

Patent Portfolio+8pts

No patents detected

✗

Government Contracts+7pts

No government contracts

✗

Late-Stage Funding+15pts

Stage: public

✓

Significant Capital+12pts

$1100M raised

✗

Hiring Acceleration+8pts

Normal hiring pace

✗

Team Depth+8pts

Limited team visibility

✗

Recent Fundraise+7pts

No recent funding

Investor Quality

18%

Avg IPO Rate

Founders Fund

Palantir, SpaceX, Affirm

22%

IPO rate

Y Combinator

DoorDash, Coinbase, Airbnb

IPO rate

Accelerator

Coatue

DoorDash, Snap, Instacart

25%

IPO rate

Growth

Executive Team

0 tracked

No team members tracked yet.

Talent Sources

Where this team came from — who they stole from

Limited talent history available. Research task recommended.

Strategic Backers

SEC Verified

High-trust data source

Public companies with strategic investments in Recursion Pharmaceuticals — sourced from SEC filings and verified disclosures.

NVIDIA

CEO: Jensen Huang

$50MPress Release

Strategic Investment · Jul 2023

AI drug discovery validates GPU computing in life sciences. Recursion uses massive GPU clusters for biological data analysis and molecular simulation.

GPU demand expansion into biotechAI drug discovery market validationDGX Cloud customer acquisition

Signal History

0 signals

No signals captured yet.